Medicines & supplements – Current GIS Alerts 2026
Found 734 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Medoxa
The National Medicines Institute reported an out-of-specification result for the parameter "appearance": tablets were non-homogeneous and some had an additional score line; during packaging, thicker and broken tablets were also found. Potential effects: improper dosing of the drug, reduced efficacy or increased adverse reactions.
Femoston
Incorrectly applied ATD safety seal on the packaging makes it impossible to reliably confirm that the pack remained unopened, so interference with the packaging and contents cannot be excluded, creating a risk of dispensing a product of unverified origin and authenticity. Potential effects: exposure to falsified, ineffective or composition-unknown product.
Reparil Gel N
An out-of-specification (OOS) result was obtained in stability testing for the parameter aescin content, indicating that the product does not meet the established quality requirements in this respect. Potential effects: reduced treatment efficacy or increased risk of adverse reactions.
Kidofen
An exceedance of the quality specification limit for the parameter "each single impurity" was found in batch No. 02AF1024. The authority states that a risk to human health from keeping this batch on the market, when used in children, cannot be excluded. Potential effects: possible toxic effects or reduced treatment safety.
Veriflo
The National Medicines Institute found that the product does not meet quality requirements due to incorrect mean content of fluticasone and salmeterol per dose and lack of dose uniformity between containers. Potential effects: lack of treatment efficacy, worsening of asthma or COPD symptoms.
Octenisept (0,10 g + 2 g)/100 g 50ml
The product was falsified, manufactured outside the authorised process and without GMP oversight, which means no guarantee of its quality. Keeping such a product on the market poses a direct and real threat to patients' health. Potential effects: lack of treatment efficacy, infections, skin or systemic complications.
Grofibrat 200
In long-term stability testing of Grofibrat 200, an out-of-specification (OOS) result was found for the active substance release parameter, meaning that quality requirements were not met during the shelf-life of batch H36032A. Potential effects: reduced treatment efficacy, possible disease progression, lack of expected therapeutic effect.
Kwas traneksamowy Tillomed
The quality defect consisting in the presence of particles visible to the naked eye in a parenterally administered product may pose a serious risk to the patient's health and life. Potential effects: serious complications, embolism by particles, life-threatening condition.
Loperamid APTEO MED
A stability test showed the active substance content below the lower specification limit, meaning the batch does not meet quality requirements and may not provide the intended therapeutic effect. Potential effects: lack of antidiarrheal efficacy, possible worsening of symptoms and complications of the underlying disease.
Lorafen
The confirmed non-compliance in the release of the active substance affects product quality and does not exclude an impact on efficacy and safety of use, nor the risk to human health or life. Potencjalne skutki: lack of efficacy, symptom worsening, complications, risk to health or life.
Carmustine Accord
The solvent component of the medicine does not meet quality requirements due to multiple exceedances of the residue after evaporation limit. Analyses indicate contamination with non-volatile residue originating from silicone tubing used for product transfer during manufacturing. Potential effects: no assurance of quality and safety of an infusion product, risk of unpredictable adverse reactions.
Taromentin
It was found that in the carton of Taromentin 1000 mg + 200 mg (batch 2010525) there was a vial of Taromentin 500 mg + 100 mg, containing half the dose of active substances, which may lead to insufficient therapeutic efficacy. Potential effects: lack of treatment efficacy, possible infection-related complications.
Zoledronic Acid Noridem
The tested sample of Zoledronic Acid Noridem 4 mg/5 ml, concentrate for solution for infusion, failed appearance requirements due to the presence of particles visible to the naked eye in the solution. Potencjalne skutki: thromboembolic complications, vascular damage, lack of safety of intravenous therapy.
Plerixafor MSN
Tests by the National Medicines Institute showed that the product fails quality requirements due to contamination with particles visible to the naked eye in the solution for injection. Potential effects: complications after intravenous or subcutaneous use, inflammatory reactions, embolism, life-threatening events.
Furaginum MAX US Pharmacia
NIL testing showed that the product does not meet quality requirements due to a failed test for nitrosamine content: NDMA, indicating contamination of the product with a potentially carcinogenic compound. Potential effects: chronic exposure, increased cancer risk, possible other toxic effects.
Skinsept Mucosa
Stability studies of batch 2434LH0503 showed an out-of-specification result for a single unidentified impurity and a borderline result for impurity K; the application to widen specification limits was rejected. Potential effects: possible quality non-compliance and uncertain treatment efficacy.
Syntarpen
A risk of microbiological contamination has been identified in batch 2031025 of this parenteral product (powder for solution for injection), which may lead to increased risk to patient health and inadequate medicinal product quality. Potential effects: infections, sepsis, serious complications, lack of treatment efficacy.
Locametz
A single unknown impurity exceeding the quality specification limit was found in batch PG21PL2505, which may affect the medicinal product's quality and does not allow exclusion of a risk to human health. Potential effects: possible unexpected adverse reactions or lack of full certainty regarding treatment safety.
Egoropal
Serious deficiencies were detected in aseptic manufacturing, creating a threat to product quality. A risk to patients' health or life cannot be excluded, particularly due to the parenteral injectable form of the medicine. Potential effects: infection, severe injection-related complications, lack of therapeutic efficacy.
Egoropal
A routine FDA inspection revealed serious deficiencies in aseptic manufacturing processes. For a prolonged-release suspension for injection, non-compliance at the sterile manufacturing stage may translate into increased risk to patients' health; a risk to life cannot be excluded. Potential effects: infection, poisoning, severe systemic complications, lack of therapeutic efficacy.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.